SAN DIEGO, March 15, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the appointment of Barry A. Labinger to its Board of Directors. Mr. Labinger is Executive Vice President and Chief Commercial Officer of Human Genome Sciences.
"We are very pleased to have Barry join our Board," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Anadys. "His impressive commercial credentials and product marketing savvy enhance our Board's collective expertise."
Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, added, "Our product candidates, ANA598 and ANA773, are advancing toward a future HCV treatment landscape based on combination regimens. Barry's perspective will be invaluable as we optimize our development plans to reflect commercial utility as part of these combination regimens."
Mr. Labinger has served as Executive Vice President and Chief Commercial Officer of Human Genome Sciences since August 2005. Mr. Labinger has more than 20 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Prior to joining Human Genome Sciences, Mr. Labinger served as Division Vice President of 3M Pharmaceuticals, a global division of 3M Company, with marketed products in dermatology, women's health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University.
"I am delighted to join the Anadys Board of Directors," said Mr. Labinger. "Anadys is a thriving biopharmaceutical company developing two promising clinical-stage assets in a very dynamic therapeutic space. This is an exciting opportunity for me and I look forward to being a part of Anadys during this pivotal stage of its development."
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is conducting a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C. The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' plans to optimize its development plans and advance ANA598 and ANA773 toward a future HCV treatment landscape based on combination regimens. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its non-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2010. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.